Phathom Pharmaceuticals Names Basta President, CEO as Curran Resigns

Dow Jones
04-01
 

By Colin Kellaher

 

Phathom Pharmaceuticals said Terrie Curran has resigned as president, chief executive and a member of the board for personal reasons.

Phathom on Tuesday said Steven Basta, who most recently served as CEO of anti-infective therapies company SaNOtize, has joined the Florham Park, N.J., biopharmaceutical company as president, CEO and a director.

Phathom said Basta, 59 years old, will receive an initial annual base salary of $700,000 and an annual bonus with a target of 70% of his base pay.

The company said Curran, who joined as CEO in 2019, will receive severance benefits that include a continuation of her base salary through June 30, 2026, and a lump sum equal to her target bonus for 2025.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

April 01, 2025 08:48 ET (12:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10